SOLICITATION NOTICE
66 -- Acquisition of a 3T MRI for Dynamic Metabolic Imaging using Dynamic Nuclear Polarization
- Notice Date
- 9/2/2017
- Notice Type
- Presolicitation
- NAICS
- 334516
— Analytical Laboratory Instrument Manufacturing
- Contracting Office
- Department of Health and Human Services, National Institutes of Health, National Cancer Institute, Office of Acquisitions, 9609 Medical Center Drive, Room 1E128, Rockville, Maryland, 20852, United States
- ZIP Code
- 20852
- Solicitation Number
- N02RC72595-76
- Archive Date
- 9/13/2017
- Point of Contact
- Catherine Muir, Phone: (240) 276-5434
- E-Mail Address
-
muirca@mail.nih.gov
(muirca@mail.nih.gov)
- Small Business Set-Aside
- N/A
- Description
- Contracting Office Address: Department of Health and Human Services, National Institutes of Health, National Cancer Institute, Office of Acquisitions, 9609 Medical Center Drive, Room 1E144, Bethesda, MD 20892, USA. Description: National Cancer Institute (NCI), Center for Cancer Research (CCR), Radiation Biology Branch (RBB), plans to procure on a sole source basis a 3T MRI for dynamic metabolic imaging using dynamic nuclear polarization that is manufactured by Bruker Biospin Corp.; 15 Fortune Drive; Billerica, MA 01821 USA. The response close date of this notice for this requirement is in accordance with FAR 5.203(a)(1). This acquisition will be processed under FAR Part 12 - Acquisition for Commercial Items and in accordance with simplified acquisition procedures as stated in FAR Part 13.106-1(b)(2), and is exempt from the requirements of FAR Part 6. The North American Industry Classification System code is 334516 and the business size standard is 1,000 employees. Only one award will be made as a result of this solicitation. This will be awarded as a firm fixed price type contract. The magnet, console, and all associated machinery and instrumentation shall be delivered and installed within seven (7) months of the purchase order award. It has been determined there are no opportunities to acquire green products or services for this procurement. The Radiation Biology Branch research activities are focused on pre-clinical basic science research aimed at identifying and incorporating novel approaches to cancer treatment, evaluation, and prevention. A variety of approaches are evaluated at the molecular, biochemical, cellular, and physiological levels including the impact of the tumor microenvironment and metabolic mutations to improve cancer treatment. Intentional or accidental exposure of humans to ionizing radiation or a course of definitive radiation therapy can lead to cancer induction or second malignancies. Research studies are directed to identify interventions to delay or prevent radiation-induced cancer after the exposure has occurred. Emphasis is placed on gaining a better understanding of the mechanisms of cell killing and protection and the activation/inhibition of complex signaling pathways mediated by oxidative stress, including ionizing radiation, reactive oxygen species (ROS), and reactive nitrogen species (RNS). A variety of cancer treatment modalities including ionizing radiation, cytotoxic and non-cytotoxic drugs, combinations of drugs and radiation, various enzymatic inhibitors, antioxidants, and a variety of agents that impose oxidative stress are used to reduce tumor growth, enhance the radiosensitivity of tumors, protect normal tissues against radiation damage, or decrease metastatic phenotypes. Additionally, chronic inflammation within the tumor microenvironment or within radiation-damaged normal tissues can result in generation of ROS and RNS and means of inhibiting inflammation by use of inhibitors of inducible nitric oxide synthase (iNOS), COX-2 inhibitors, and nitroxide antioxidants are being investigated. Novel functional imaging approaches including non-invasive measurement of tissue oxygen concentration and metabolism as measured by C13-pyruvate are being implemented as a means of improving cancer diagnosis, guiding individualized therapies, and temporal assessment of treatment response. The development, testing, refinement, and application of low-frequency electron paramagnetic resonance (EPR) functional imaging devices suitable for in vivo imaging of paramagnetic species has resulted in a prototype scanner for small animals that non-invasively measures tissue oxygen concentration. The ability to acquire multiple images over time is a unique feature of this novel imaging technology permitting monitoring physiological changes in the tumor in response to therapy. Pre-clinical metabolic imaging using hyperpolarized metabolic substrates is also being developed to access tumor response following various cancer treatment modalities as well as metabolically directed inhibitors. The Contractor shall provide the following salient physical, functional, and performance characteristics, inclusive of hardware and/or software specifications, that are deemed essential to the needs of the Government: PRODUCT FEATURES/SALIENT CHARACTERISTICS The following product features/characteristics are deemed essential for this requirement: • Closed helium recycling system • Three hour magnet hold time • 13C quadrature detection • Hot fix capable • Ultra-short and zero echo sequences for imaging tissues with short T2 times • To be compatible with control software of the existing 1 T MRI scanner operating on Paravision 5.0 platform • A bore size large enough for a rat or large mouse (at least 18 cm) • A field of view of at least 100 mm x 70 mm • Less than 0.1 ppm magnetic inhomogeneity over the field of view • To transmit and receive broadband RF channels for 1H/13C and 15N/1H experiments. • High power, second order shimming using phase mapping. The improved shimming from the use of high power second order gradients are essential in resolving 1H and 13C spectra. • Upgrade capability to a liquid nitrogen or liquid helium cryoprobe. The cryoprobe provides a substantial increase in signal to noise ratio. A cryoprobe is not provided for in the current procurement quote but should be available for a future upgrade. DELIVERY / INSTALLATION Delivery address:NIH / NCI / CCR 9000 Rockville Pike Building 10, Room B3 B48 Bethesda, MD 20892 TRAINING This acquisition includes a full battery of instrument calibration standards to be used during and following installation. Also included are eight (8) days tuition to Vendor training courses for no less than three (3) CCM facility staff. CONSIDERATION AND PAYMENT Payment shall be made in arrears after delivery, installation, inspection and acceptance, and successful completion of the required training stated above. Payment authorization requires submission and approval of invoices to the NCI Technical Point of Contact and the NIH Office of Financial Management (OFM), in accordance with the payment provisions in the order. The following clause is applicable to all Purchase Orders, Task or Delivery Orders, and Blanket Purchase Agreement (BPA) Calls: PROMPT PAYMENT (JUL 2013) FAR 52.232-25. This equipment is manufactured by Bruker Biospin Corp. The proposed source is the only known source on the market that provides an instrument with all of the technical requirements stated in the Statement of Need required for the cancer metabolism research being conducted at the NCI. Although several 3T MRI scanners are installed in Building 10, the physics of the DNP process place severe restrictions on the placement of the MRI scanner for the technique. A 3T MRI optimized for 13C and 15N metabolic imaging is needed to meet this existing constraint. There is no comparable technology to the 3T scanner with a closed helium recycling system nor other viable sources available in order to advance the CCR's scientific mission. The proposed equipment is essential to the Government's requirement, and market research indicates there are no other companies with a similar product to meet the Government's needs. This notice is not a request for competitive quotation. However, if any interested party, especially small businesses, believes it can meet the above requirement, it may submit a capability statement, proposal, or quotation, which shall be considered by the agency. The statement of capabilities and any other information furnished must be in writing and must contain material in sufficient detail to allow NCI to determine if the party can perform the requirement. Responses must be received in the contracting office by 2:30PM EDT, on Sept. 12, 2017. All responses and questions must be in writing and faxed (240) 276-5401 or emailed to Catherine Muir, Contracting Officer via electronic mail at muirca@mail.nih.gov. A determination by the Government not to compete this proposed requirement based upon responses to this notice is solely within the discretion of the Government. Information received will be considered solely for the purpose of determining whether to conduct a competitive procurement. No collect calls will be accepted. In order to receive an award, Contractors must be registered and have valid, current Entity Record, including current Representations and Certifications, in the System for Award Management (SAM) through SAM.gov. Reference: N02RC72595-76 on all correspondence.
- Web Link
-
FBO.gov Permalink
(https://www.fbo.gov/spg/HHS/NIH/RCB/N02RC72595-76/listing.html)
- Record
- SN04660409-W 20170904/170902230139-fbf9bab585543009715640581e54f237 (fbodaily.com)
- Source
-
FedBizOpps Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's FBO Daily Index Page |